Immune checkpoint inhibitors (ICIs) are a novel class of immunotherapy drugs that have
improved the treatment of a broad spectrum of cancers as metastatic melanoma, non-small …

Effective immunosupression management is central to achieving optimal outcomes in liver
transplant recipients. Current immunosuppression regimens and agents are highly effective …

Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in
the white populations, accounting for 20% of all cutaneous malignancies. Factors implicated …

Short-term patient and graft outcomes continue to improve after kidney and liver
transplantation, with 1-year survival rates over 80%; however, improving longer-term …

Systematic reviews are increasingly utilized in the medical literature to summarize available
evidence on a research question. Like other studies, systematic reviews are at risk for bias …

Cancer is the second most common cause of mortality and morbidity in kidney transplant
recipients after cardiovascular disease. Kidney transplant recipients have at least a twofold …

Long-term utilization of immunosuppression in organ transplant recipients (OTRs) leads to
decreased immune-mediated tumor surveillance and development of malignant tumors. A …

These guidelines cover the care of patients from the period following kidney transplantation
until the transplant is no longer working or the patient dies. During the early phase …

The long-term management of maintenance immunosuppression in kidney transplant
recipients remains complex. The vast majority of patients are treated with the calcineurin …

Post‐transplant diabetes mellitus (PTDM) shows a relationship with risk factors including
obesity and tacrolimus‐based immunosuppression, which decreases pancreatic insulin …